Literature DB >> 20203258

Dynamic calibration of pharmacokinetic parameters in dose-finding studies.

John O'Quigley1, Michael D Hughes, Terry Fenton, Lixia Pei.   

Abstract

We introduce a dose-finding algorithm to be used to identify a level of dose that corresponds to some given targeted response. Our motivation arises from problems where the response is a continuously measured quantity, typically some pharmacokinetic parameter. We consider the case where an agreed level of response has been determined from earlier studies on some population and the purpose of the current trial is to obtain the same, or a comparable, level of response in a new population. This relates to bridging studies. The example driving our interest comes from studies on drugs for HIV that have already been evaluated in adults and where the new studies are to be carried out in children. These drugs have the ability to produce some given mean pharmacokinetic response in the adult population, and the goal is to calibrate the dose in order to obtain a comparable response in the childhood population. In practice, it may turn out that the dose producing some desired mean response is also associated with an unacceptable rate of toxicity. In this case, we may need to reevaluate the target response and this is readily achieved. In simulations, the algorithm can be seen to work very well. In the most challenging situations for the method, those where the targeted response corresponds to a region of the dose-response curve that is relatively flat, the algorithm can still perform satisfactorily.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203258      PMCID: PMC2883303          DOI: 10.1093/biostatistics/kxq002

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  2 in total

1.  Dose-finding designs for HIV studies.

Authors:  J O'Quigley; M D Hughes; T Fenton
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

  2 in total
  4 in total

1.  Sequential monitoring of Phase I dose expansion cohorts.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2016-02-07       Impact factor: 2.373

2.  Dose expansion cohorts in Phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Biopharm Res       Date:  2016-06-02       Impact factor: 1.452

3.  Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.

Authors:  Moreno Ursino; Sarah Zohar; Frederike Lentz; Corinne Alberti; Tim Friede; Nigel Stallard; Emmanuelle Comets
Journal:  Biom J       Date:  2017-03-21       Impact factor: 2.207

4.  Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.

Authors:  Sandrine Micallef; Alexandre Sostelly; Jiawen Zhu; Paul G Baverel; Francois Mercier
Journal:  Contemp Clin Trials Commun       Date:  2022-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.